Cervix Lesion, Papilloma
Conditions
Brief summary
To test the efficacy of a newly-commercialized formula, 40 HPV-positive women displaying chronic cervicitis, mild dysplasia or moderate dysplasia. Women in the study group took one tablet per day containing 200 mg of EGCG, 400 mcg of Folic Acid, 1 mg of Vitamin B12 and 50 mg of Hyaluronic Acid for twelve weeks. Women in the control group received no treatment.
Interventions
DIETARY_SUPPLEMENTEpigallocatechin gallate, Folic acid, Vitamin B12, and Hyaluronic Acid
One tablet per day containing 200 mg of EGCG, 400 mcg of Folic Acid, 1 mg of Vitamin B12 and 50 mg of Hyaluronic Acid.
Sponsors
Lo.Li.Pharma s.r.l
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
40 HPV-positive women displaying chronic cervicitis, mild dysplasia or moderate dysplasia.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* HPV infections * Occurrence of low-grade cervical lesions
Exclusion criteria
* Diagnosis of malignancy or severe cervical lesions * Concurrent uterine pathologies * Pregnancy or intended to seek pregnancy in the next three months * Cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Regression of cervical lesions | 12 weeks | The actual outcome was to measure the rate of regression of the lesions, from moderate to mild, from mild to none. |
Countries
Italy
Outcome results
None listed